SK11732001A3 - Deriváty beta-alanínu - Google Patents
Deriváty beta-alanínu Download PDFInfo
- Publication number
- SK11732001A3 SK11732001A3 SK1173-2001A SK11732001A SK11732001A3 SK 11732001 A3 SK11732001 A3 SK 11732001A3 SK 11732001 A SK11732001 A SK 11732001A SK 11732001 A3 SK11732001 A3 SK 11732001A3
- Authority
- SK
- Slovakia
- Prior art keywords
- ylamino
- propionic acid
- acetylamino
- nitrophenyl
- methylpyridin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/30—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
- C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19907370 | 1999-02-20 | ||
| DE19957787 | 1999-12-01 | ||
| PCT/EP2000/000969 WO2000048996A2 (de) | 1999-02-20 | 2000-02-08 | Beta-alaninderivate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK11732001A3 true SK11732001A3 (sk) | 2002-04-04 |
Family
ID=26051970
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK1173-2001A SK11732001A3 (sk) | 1999-02-20 | 2000-02-08 | Deriváty beta-alanínu |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US6576637B1 (zh) |
| EP (1) | EP1153014B1 (zh) |
| JP (1) | JP2002537287A (zh) |
| KR (1) | KR20010093303A (zh) |
| CN (1) | CN1146541C (zh) |
| AR (1) | AR022628A1 (zh) |
| AT (1) | ATE277016T1 (zh) |
| AU (1) | AU760246B2 (zh) |
| BR (1) | BR0008310A (zh) |
| CA (1) | CA2371824A1 (zh) |
| CZ (1) | CZ20012785A3 (zh) |
| DE (1) | DE50007899D1 (zh) |
| DK (1) | DK1153014T3 (zh) |
| ES (1) | ES2228472T3 (zh) |
| HK (1) | HK1042894A1 (zh) |
| HU (1) | HUP0105479A3 (zh) |
| NO (1) | NO20014010L (zh) |
| PL (1) | PL350057A1 (zh) |
| PT (1) | PT1153014E (zh) |
| SK (1) | SK11732001A3 (zh) |
| WO (1) | WO2000048996A2 (zh) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10041423A1 (de) * | 2000-08-23 | 2002-03-07 | Merck Patent Gmbh | Biphenylderivate |
| DE10112771A1 (de) * | 2001-03-16 | 2002-09-26 | Merck Patent Gmbh | Inhibitoren des Integrins alpha¶v¶beta¶6¶ |
| DE10118550A1 (de) * | 2001-04-14 | 2002-10-17 | Merck Patent Gmbh | Liganden des Integrins alpha¶nu¶beta¶6¶ |
| DE10127041A1 (de) * | 2001-06-02 | 2002-12-05 | Merck Patent Gmbh | Integrinantagonisten |
| DE10139059A1 (de) * | 2001-08-08 | 2003-02-20 | Merck Patent Gmbh | Thioamide |
| DE10204789A1 (de) * | 2002-02-06 | 2003-08-14 | Merck Patent Gmbh | Inhibitoren des Integrins alpha¶v¶beta6 |
| EP1590366B1 (de) * | 2003-02-06 | 2008-05-07 | MERCK PATENT GmbH | Peptidische sulfonamide |
| US20050107350A1 (en) * | 2003-08-22 | 2005-05-19 | Pharmacia Corporation | Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith |
| CA2540730C (en) * | 2003-10-01 | 2012-08-21 | Merck Patent Gmbh | Alfavbeta3 and alfavbeta6 integrin antagonists as antifibrotic agents |
| AU2005249586B2 (en) | 2004-06-04 | 2010-12-23 | The Scripps Research Institute | Compositions and methods for treatment of neovascular diseases |
| EP2730282A1 (en) | 2007-11-08 | 2014-05-14 | The General Hospital Corporation | Methods and compositions for the treatment of proteinuric diseases |
| EP2666365A1 (en) * | 2012-05-22 | 2013-11-27 | Taminco | Treatment of poultry, pigs or fish for reducing the feed conversion ratio. |
| CN104027805B (zh) * | 2014-06-18 | 2017-02-15 | 北京大学 | 抑制整合素α5的物质在制备预防内皮细胞激活和/或动脉粥样硬化的产品中的新用途 |
| TN2020000059A1 (en) * | 2017-11-01 | 2022-01-06 | Arrowhead Pharmaceuticals Inc | Integrin ligands and uses thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1209063A (zh) | 1995-12-29 | 1999-02-24 | 史密丝克莱恩比彻姆公司 | 玻连蛋白受体拮抗剂 |
| CA2242877A1 (en) * | 1996-01-16 | 1997-07-24 | Merck & Co., Inc. | Integrin receptor antagonists |
| GB2327609A (en) | 1997-07-23 | 1999-02-03 | Merck & Co Inc | A method for eliciting an avß5 or dual avß3/avß5 antagonizing effect |
-
2000
- 2000-02-08 PT PT00909151T patent/PT1153014E/pt unknown
- 2000-02-08 US US09/913,933 patent/US6576637B1/en not_active Expired - Fee Related
- 2000-02-08 AU AU31534/00A patent/AU760246B2/en not_active Ceased
- 2000-02-08 DK DK00909151T patent/DK1153014T3/da active
- 2000-02-08 SK SK1173-2001A patent/SK11732001A3/sk unknown
- 2000-02-08 CA CA002371824A patent/CA2371824A1/en not_active Abandoned
- 2000-02-08 PL PL00350057A patent/PL350057A1/xx unknown
- 2000-02-08 JP JP2000599737A patent/JP2002537287A/ja not_active Withdrawn
- 2000-02-08 WO PCT/EP2000/000969 patent/WO2000048996A2/de not_active Application Discontinuation
- 2000-02-08 HU HU0105479A patent/HUP0105479A3/hu unknown
- 2000-02-08 AT AT00909151T patent/ATE277016T1/de not_active IP Right Cessation
- 2000-02-08 CN CNB008038422A patent/CN1146541C/zh not_active Expired - Fee Related
- 2000-02-08 ES ES00909151T patent/ES2228472T3/es not_active Expired - Lifetime
- 2000-02-08 BR BR0008310-0A patent/BR0008310A/pt not_active IP Right Cessation
- 2000-02-08 EP EP00909151A patent/EP1153014B1/de not_active Expired - Lifetime
- 2000-02-08 DE DE50007899T patent/DE50007899D1/de not_active Expired - Fee Related
- 2000-02-08 KR KR1020017009642A patent/KR20010093303A/ko not_active Application Discontinuation
- 2000-02-08 CZ CZ20012785A patent/CZ20012785A3/cs unknown
- 2000-02-18 AR ARP000100693A patent/AR022628A1/es not_active Application Discontinuation
-
2001
- 2001-08-17 NO NO20014010A patent/NO20014010L/no not_active Application Discontinuation
-
2002
- 2002-05-31 HK HK02104088.3A patent/HK1042894A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2002537287A (ja) | 2002-11-05 |
| WO2000048996A3 (de) | 2000-11-16 |
| AU760246B2 (en) | 2003-05-08 |
| DE50007899D1 (de) | 2004-10-28 |
| KR20010093303A (ko) | 2001-10-27 |
| PT1153014E (pt) | 2005-02-28 |
| EP1153014B1 (de) | 2004-09-22 |
| ES2228472T3 (es) | 2005-04-16 |
| AR022628A1 (es) | 2002-09-04 |
| CZ20012785A3 (cs) | 2001-11-14 |
| CN1146541C (zh) | 2004-04-21 |
| CA2371824A1 (en) | 2000-08-24 |
| PL350057A1 (en) | 2002-11-04 |
| HK1042894A1 (zh) | 2002-08-30 |
| US6576637B1 (en) | 2003-06-10 |
| CN1340046A (zh) | 2002-03-13 |
| DK1153014T3 (da) | 2005-01-24 |
| HUP0105479A2 (hu) | 2002-04-29 |
| NO20014010L (no) | 2001-10-18 |
| WO2000048996A2 (de) | 2000-08-24 |
| AU3153400A (en) | 2000-09-04 |
| ATE277016T1 (de) | 2004-10-15 |
| EP1153014A2 (de) | 2001-11-14 |
| BR0008310A (pt) | 2002-01-22 |
| HUP0105479A3 (en) | 2002-06-28 |
| NO20014010D0 (no) | 2001-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1377540B1 (en) | Inhibitors of integrin alpha-v-beta-6 | |
| KR20000022190A (ko) | 인테그린 저해제로서의 페닐알라닌 유도체 | |
| US6576637B1 (en) | β-alanine derivatives | |
| SK412001A3 (en) | Diacylhydrazine derivatives as integrin inhibitors | |
| AU2002254900A1 (en) | Inhibitors of integrin AlphavBeta6 | |
| CZ20011515A3 (cs) | Derivát chromenonu a chromanonu jakožto inhibitory integrinu | |
| US20030171304A1 (en) | Pyridine-2-yl-aminoalkyl carbonyl glycyl-$g(b)-alanine and derivatives thereof | |
| SK8182003A3 (en) | Urea and urethane derivative as integrin inhibitor, process for the preparation thereof, its use and pharmaceutical composition comprising same | |
| CZ20033000A3 (cs) | Inhibitory integrinů a(v)B6 | |
| CZ200219A3 (cs) | Derivát diacylhydrazinu, způsob jeho přípravy, jeho pouľití a farmaceutický prostředek, který ho obsahuje | |
| SK2962003A3 (en) | Biphenyl derivatives and the use thereof as integrin inhibitors | |
| RU2234496C2 (ru) | Производные бета-аланина | |
| JP2002542231A (ja) | 血栓症、骨粗鬆症、動脈硬化症を処置するためのジベンゾアズレン誘導体 | |
| MXPA01008424A (en) | &bgr;-ALANINE DERIVATIVES | |
| KR20030022419A (ko) | 비페닐 유도체, 및 인테그린 저해제로서의 그의 용도 | |
| CZ2002298A3 (cs) | Derivát fluorenu, způsob jeho přípravy, jeho pouľití a farmaceutický prostředek, který ho obsahuje | |
| CZ2001141A3 (cs) | Derivát diacylhydrazinu jakožto integrinový inhibitor, způsob jeho přípravy, jeho použití a farmaceutický prostředek, který ho obsahuje |